Abstract
The EGADi project aims to identify innovative early biomarkers and therapeutic targets for Alzheimer's disease (AD) by investigating molecular mechanisms underlying its pathogenesis. Using advanced molecular biology techniques, EGADi will analyze biomarkers in plasma, cerebrospinal fluid, and extracellular vesicles (EVs) from healthy controls, prodromal subjects, and AD patients. The project will develop in vitro models derived from patient fibroblasts to study intercellular communication mediated by EVs. Expected outcomes include a comprehensive biomarker profile for early AD diagnosis and identification of new pharmacological targets, enabling improved diagnostic approaches and innovative treatments, ultimately promoting healthy aging and reducing the social burden of AD.
Dettagli del progetto
Responsabile scientifico: Patrizia Hrelia
Strutture Unibo coinvolte:
Dipartimento di Farmacia e Biotecnologie
Coordinatore:
ALMA MATER STUDIORUM - Università di Bologna(Italy)
Contributo totale di progetto: Euro (EUR) 300.000,00
Contributo totale Unibo: Euro (EUR) 120.000,00
Durata del progetto in mesi: 24
Data di inizio
30/11/2023
Data di fine:
28/02/2026
